Revista Colombiana de Reumatologia最新文献

{"title":"Risk predictors for adverse COVID-19 outcomes in Latin American patients with autoimmune rheumatic diseases: A multicentre study in Ecuador and Mexico","authors":"Santiago Guzmán-García ,&nbsp;Goethe Sacoto-Flores ,&nbsp;Johanna Román-Bermeo ,&nbsp;Fabiana Samaniego-Burneo ,&nbsp;María Ochoa ,&nbsp;Franklin Uguña-Sari ,&nbsp;Gladis Molina-Alvarado ,&nbsp;Luis M. Amezcua-Guerra","doi":"10.1016/j.rcreu.2024.02.004","DOIUrl":"10.1016/j.rcreu.2024.02.004","url":null,"abstract":"<div><h3>Introduction/objectives</h3><div>The understanding of COVID-19 progression among patients with autoimmune rheumatic diseases (SARDs) in Latin America remains limited. This study aimed to identify risk predictors associated with poor outcomes of COVID-19 in patients with SARDs.</div></div><div><h3>Materials and methods</h3><div>An observational multicentre study including patients with SARDs from Ecuador and Mexico.</div></div><div><h3>Results</h3><div>A total of 103 patients (78% women), aged 52.5<!--> <!-->±<!--> <!-->17.7 years, were enrolled. The most prevalent SARDs were rheumatoid arthritis (59%) and systemic lupus erythematosus (SLE; 24%). Severe COVID-19 was observed in 28% of patients at admission, 43% experienced complications during follow-up, and 8% ultimately died. Mortality rates were highest in patients with antiphospholipid syndrome (27%) or SLE (20%). Poor prognostic factors included acute respiratory distress syndrome (odds ratio [OR]<!--> <!-->=<!--> <!-->17.07), severe COVID-19 at admission (OR<!--> <!-->=<!--> <!-->11.45), and presence of SLE (OR<!--> <!-->=<!--> <!-->4.62). In multivariate analysis, SLE emerged as the sole predictor of mortality (OR<!--> <!-->=<!--> <!-->15.61).</div></div><div><h3>Conclusions</h3><div>Patients with SARDs in Latin America face significant risks of adverse COVID-19 outcomes, with SLE being a major risk factor for mortality.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 152-158"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efectividad del uso del parche de trinitrato de glicerilo en el fenómeno de Raynaud secundario","authors":"Silvia Méndez-Flores ,&nbsp;Dulce María Carrillo-Córdova ,&nbsp;Rafael López-Loya ,&nbsp;Bruno Estañol-Vidal","doi":"10.1016/j.rcreu.2024.01.002","DOIUrl":"10.1016/j.rcreu.2024.01.002","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>Secondary Raynaud's phenomenon is one of the primary cutaneous manifestations of various rheumatological diseases, which can significantly impact quality of life and whose systemic treatment can lead to several adverse effects. Therefore, this study was conducted to assess the effectiveness of glyceryl trinitrate (in transdermal patch form) in patients with secondary Raynaud's phenomenon (SRP), evaluated through vascular flow photoplethysmography.</div></div><div><h3>Materials and methods</h3><div>A comparative, analytical, open-label, non-randomized study was conducted to evaluate the efficacy of 4.5<!--> <!-->mg of glyceryl trinitrate in a transdermal patch placed on the proximal region of one hand in patients diagnosed with SRP compared to the untreated contralateral hand. To determine the primary outcome, vascular flow photoplethysmography assessment was performed 30 days after daily patch use. Secondary results were obtained using an infrared thermometer to measure local temperature in both hands before patch application, 30<!--> <!-->minutes after patch use, and at the end of the follow-up period. Additionally, various questionnaires, including the Visual Analogue Scale for pain, Raynaud's Condition Score (RCS), and Dermatology Quality of Life Index (DLQI), were administered on the first and last days of the study.</div></div><div><h3>Results</h3><div>Sixteen patients, all female, with a median age of 54 years, were included. Regarding the rheumatological diseases associated with secondary Raynaud's phenomenon, twelve patients (75% of the sample) were associated with systemic sclerosis, three patients (19%) with lupus erythematosus, and one (6%) with mixed connective tissue disease (MCTD). There was a significant increase in peripheral blood flow after 30 days of treatment with 4.5<!--> <!-->mg of glyceryl trinitrate every 24<!--> <!-->hours, along with improvement in clinical symptom and quality of life questionnaires.</div></div><div><h3>Conclusions</h3><div>This study supports the use of low-dose glyceryl trinitrate via transdermal patches to improve vascular flows, translating into short-term clinical symptom improvement associated with SRP.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 130-136"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140274548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"El ABC de la nefritis lúpica","authors":"José A. Gómez-Puerta","doi":"10.1016/j.rcreu.2025.02.001","DOIUrl":"10.1016/j.rcreu.2025.02.001","url":null,"abstract":"","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 103-104"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comite Editorial online","authors":"","doi":"10.1016/S0121-8123(24)00107-5","DOIUrl":"10.1016/S0121-8123(24)00107-5","url":null,"abstract":"","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages E1-E3"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143767988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge of medications and understanding of Mexican patients regarding the non-medical switch from originator to its biosimilar in inflammatory arthritis","authors":"Carlos Andrés Díaz-Garza ,&nbsp;Alejandro Garza-Alpirez ,&nbsp;David Vega-Morales ,&nbsp;Deshiré Alpizar-Rodríguez ,&nbsp;Berenice Carrillo-Haro","doi":"10.1016/j.rcreu.2023.12.007","DOIUrl":"10.1016/j.rcreu.2023.12.007","url":null,"abstract":"<div><h3>Introduction/Objective</h3><div>Our aim was to know patient's understanding and concerns about biosimilars, switching, and non-medical switch in Mexican population.</div></div><div><h3>Materials and methods</h3><div>A cross-sectional social media survey via the Mexican Foundation for Rheumatic Patients (FUMERAC) was conducted from November 2020 to January 2021. Patients were eligible if they were &gt;18 years of age with any inflammatory rheumatic condition.</div></div><div><h3>Results</h3><div>A total of 165 participants completed the survey. The most frequent diagnoses were Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis. Disease-modifying antirheumatic drugs as monotherapy was the most common treatment. Prior or current users of biologics were reported. Most participants had never heard the term biosimilar<span>. Some would accept the change from an originator to its biosimilar and few would take legal measure or file a complaint if a non-medical switch were to happen. Patients had concerns on treatment effectiveness, adverse effects, reason for change, treatment duration, and other patient's experience.</span></div></div><div><h3>Conclusion</h3><div>In Mexico, the concept of biosimilars is barely known. Most patients would not take any measure if they were changed from an originator to its biosimilar.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 105-109"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140091455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of simple hematological parameters with disease activity and damage indices among Egyptian patients with systemic lupus erythematosus","authors":"Hanan H. Ahmed ,&nbsp;Hebatallah S. Farag ,&nbsp;Nesreen Sobhy","doi":"10.1016/j.rcreu.2024.01.006","DOIUrl":"10.1016/j.rcreu.2024.01.006","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the correlation of different hematological parameters in lupus patients with SLE disease activity index (SLEDAI), the Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI), and some laboratory data related to kidney functions in active patients with nephritis.</div></div><div><h3>Material and methods</h3><div>80 inactive SLE patients (SLEDAI score<!--> <!-->&lt;<!--> <!-->10 points), and 80 active patients (SLEDAI<!--> <!-->≥<!--> <span>10 points) were enrolled in this study. All patients underwent full medical history taking, clinical evaluation including calculation of SLEDAI<span> and SLICC/ACR DI scores, and laboratory investigations including complete blood count. The two groups were compared regarding different disease parameters. Correlations of some hematological parameters with SLEDAI, SLICC/ACR DI scores and some laboratory data related to kidney function in patients with nephritis were made.</span></span></div></div><div><h3>Results</h3><div>The active group showed statistically significantly higher mean NLR (<em>P</em> <!-->=<!--> <!-->0.000), NC3R (<em>P</em> <!-->=<!--> <!-->0.000), MLR (<em>P</em> <!-->=<!--> <!-->0.000), PLR (<em>P</em> <!-->=<!--> <!-->0.000), and RDW (<em>P</em> <!-->=<!--> <!-->0.001), and statistically significantly lower mean MPV (<em>P</em> <!-->=<!--> <!-->0.002). The mean MLR (<em>P</em> <!-->=<!--> <!-->0.018) and PLR (<em>P</em> <!-->=<!--> <span>0.005) were statistically significantly higher in the active patients with nephritis. For both groups, there were no significant correlations between studied parameters and SLEDAI or SLICC/ACR DI, except with NC3R values in the active group which were associated with SLEDAI (</span><em>r</em> <!-->=<!--> <!-->.221, <em>P</em> <!-->=<!--> <!-->0.049).</div></div><div><h3>Conclusion</h3><div>The hematological parameters in SLE have promising potential clinical application as a novel activity marker, especially in patients with nephritis.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 145-151"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140404698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common variable immune deficiency complicating proliferative lupus nephropathy: A diagnostic and therapeutic challenge","authors":"Lamia Bengherbia,&nbsp;Said Taharboucht,&nbsp;Oussama Souas,&nbsp;Hassina Chicha,&nbsp;Ahcene Chibane","doi":"10.1016/j.rcreu.2024.02.002","DOIUrl":"10.1016/j.rcreu.2024.02.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Common variable immunodeficiency (CVID) is a rare condition characterized by a constitutional humoral immune deficiency. Its association with systemic lupus is extremely rare.</div></div><div><h3>Case presentation</h3><div>In this case report, we present a 21-year-old woman with a history of Hashimoto's thyroiditis, who, following the onset of nephrotic syndrome revealing her lupus disease, subsequently developed clinical and laboratory features consistent with CVID, alongside recurrent lupus flares. Her initial therapeutic management was intricate, ultimately resulting in stable remission achieved through monthly immunoglobulin infusions.</div></div><div><h3>Conclusion</h3><div>This case illustrates the diagnostic and therapeutic difficulty of lupus disease and a common variable immune deficiency.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 168-172"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141041004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anemia hemolítica autoinmune por crioaglutininas asociado a lupus eritematoso sistémico. Presentación de casos y revisión de la literatura","authors":"Jaime Alberto Coral Enríquez ,&nbsp;Victoria Eugenia Cajas Bravo","doi":"10.1016/j.rcreu.2024.02.003","DOIUrl":"10.1016/j.rcreu.2024.02.003","url":null,"abstract":"<div><h3>Introduction</h3><div>Cold agglutinin autoimmune haemolytic anaemia (AIHA) secondary to systemic lupus erythematosus (SLE) is a rare manifestation. There are no cohorts or case series that allow us to evaluate the characteristics of this group of patients.</div></div><div><h3>Objective</h3><div>To describe the clinical and serological characteristics of patients with systemic lupus erythematosus (SLE) and cold agglutinin hemolytic anemia.</div></div><div><h3>Materials and methods</h3><div>We present two cases with SLE that debuted with cold agglutinin AHAI, their clinical and immunological profile and response to immunosuppressive treatment.</div></div><div><h3>Results</h3><div>Eleven cases reported in the literature from 1950 to 2023 are described.</div></div><div><h3>Conclusion</h3><div>Cold agglutinin AHAI secondary to SLE is rare, with similar clinical features compared to idiopathic forms and usually not associated with manifestations or serious organic involvement.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 2","pages":"Pages 173-179"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141043540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comite Editorial online","authors":"","doi":"10.1016/S0121-8123(24)00103-8","DOIUrl":"10.1016/S0121-8123(24)00103-8","url":null,"abstract":"","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 1","pages":"Pages E1-E3"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143133945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evidencia terapéutica del mepolizumab en la granulomatosis eosinofílica con poliangeítis: una revisión exploratoria","authors":"Eduardo Tuta-Quintero ,&nbsp;Isabella Perna-Reyes ,&nbsp;Juan Olivella-Gómez ,&nbsp;Daniela Rodríguez-Fraile ,&nbsp;Juan C. Santacruz ,&nbsp;Andrea A. Mayorga-Borja ,&nbsp;John Londoño","doi":"10.1016/j.rcreu.2023.11.003","DOIUrl":"10.1016/j.rcreu.2023.11.003","url":null,"abstract":"<div><div>Mepolizumab (MPZ) is a therapeutic option for eosinophilic granulomatosis with polyangiitis (EGPA). However, the evidence on its efficacy, effectiveness, and safety is limited. Our results included 17 full-text articles evaluating the use of MPZ in patients diagnosed with EGPA, 47% (8/17) of the documents were case reports, 18% (3/17) retrospective cohort studies, 12% (2/17) clinical trials, and 6% corresponded to a prospective cohort (1/17), ambispective cohort (1/17), case series (1/17), and pilot study (1/17). The most frequently used dose of MPZ was 300 mg/month, described in 59% (10/17) of the included manuscripts. The decrease in the Birmingham Vasculitis Activity Score (BVAS), reduction in the dose of corticosteroids, and modulation in the number of eosinophils in the blood were the variables most used to determine the clinical effect in patients. Finally, 10 clinical trial records were included describing the design, conduct, and administration of the ongoing studies. The use of MPZ in patients with EGPA shows a reduction in the BVAS, saving oral corticosteroids and modulating blood hypereosinophilia. The adverse events described were mild and moderate in all the included studies.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"32 1","pages":"Pages 69-83"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139818067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}